Corticosteroid premedication on anti-tumor effect of immune checkpoint blockade in murine hepatocellular carcinoma models
Journal for ImmunoTherapy of Cancer · 2025-02 · 13 (2) · e009704
DOI: 10.1136/jitc-2024-009704 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 20.02.2025. Verfasst von Ying-Chun Shen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Carcinoma, Hepatocellular, Adrenal Cortex Hormones, Liver Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Taiwan University Cancer Center, Ministry of Science and Technology, Taiwan, National Science and Technology Council.
Abstract (Originalsprache)
Background and aims Corticosteroid is effective in alleviating immune-related adverse events (irAEs) of immune checkpoint blockade (ICB). However, prophylactic use of corticosteroid to prevent irAEs is not recommended due to a looming concern that it may attenuate anti-tumor effect of ICB. This study aims to investigate whether corticosteroid premedication may compromise anti-tumor efficacy of dual ICB, a regimen that may cause significant irAEs.
Methods
Orthotopic BNL 1MEA.7R.1 and subcutaneous Hepa1-6 syngeneic hepatocellular carcinoma (HCC) models were used. Low-dose (LD; 10 µg) or high-dose (HD; 200 µg) dexamethasone (Dexa) was intraperitoneally administered before each dose of anti-CTLA-4 and anti-PD-1. Tumor shrinkage, T cell priming, cytokine quantitation, as well as cytotoxicity and single-cell RNA-sequencing (scRNA-seq) of tumor-infiltrating T cells were assessed.
Results
In the orthotopic model, dual immune checkpoint blockade (dICB) plus phosphate buffered saline (PBS) significantly reduced the mean tumor weight (adjusted for SE) (0.73±0.18 g vs 2.45±0.54 g; p=0.03), while neither LD nor HD Dexa premedication affected dICB-induced tumor shrinkage. In the subcutaneous model, dICB plus PBS or LD Dexa yielded a complete tumor response (CR) rate of 100%, while dICB plus HD Dexa yielded a CR rate of 85.7% (p>0.05, comparing to dICB plus PBS). ScRNA-seq analysis demonstrates that Dexa did not affect dICB-induced reduction of major clusters of exhausted CD4+ and CD8+ T cells but halved dICB-induced expansion of effector memory CD8+ T cells. Nevertheless, Dexa premedication, regardless of dosage, did not diminish dICB-induced T cell priming, cytokine production, or cytotoxicity of tumor-infiltrating CD8+ T cells.
Conclusion
Corticosteroid premedication does not significantly compromise anti-tumor efficacy of dICB treatment in murine HCC models. These results suggest that clinical investigations of prophylactic corticosteroids to alleviate severe irAEs may be feasible.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan.
- Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan.
- Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.
- Department of Medical Research, National Taiwan University Hospital, Taipei, Taiwan.
- Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan alcheng@ntu.edu.tw.
Förderung
- National Taiwan University Cancer Center
- Ministry of Science and Technology, Taiwan
- National Science and Technology Council
Zitieren
APA
Shen, Y. C., Chang, N. W., Yeh, C. P., Lin, W. Y., Wei, M. F., Ou, D. L., Hsu, C. L., & Cheng, A. L. (2025). Corticosteroid premedication on anti-tumor effect of immune checkpoint blockade in murine hepatocellular carcinoma models. Journal for ImmunoTherapy of Cancer, 13(2), e009704. https://doi.org/10.1136/jitc-2024-009704
Vancouver
Shen YC, Chang NW, Yeh CP, Lin WY, Wei MF, Ou DL, et al. Corticosteroid premedication on anti-tumor effect of immune checkpoint blockade in murine hepatocellular carcinoma models. Journal for ImmunoTherapy of Cancer. 2025;13(2):e009704. doi:10.1136/jitc-2024-009704
BibTeX
@article{Shen2025,
author = {Shen, Ying-Chun and Chang, Nai-Wen and Yeh, Ching-Ping and Lin, Wan-Ying and Wei, Ming-Feng and Ou, Da-Liang and Hsu, Chia-Lang and Cheng, Ann-Lii},
title = {Corticosteroid premedication on anti-tumor effect of immune checkpoint blockade in murine hepatocellular carcinoma models},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2025},
volume = {13},
number = {2},
pages = {e009704},
doi = {10.1136/jitc-2024-009704}
}
EUVIMED